Tanja Obradovic: Gursel Aktan and Merck women’s cancer team on just released positive OS data on KN 522
Tanja Obradovic shared a post on LinkedIn:
“Congratulations to amazing leader in immunooncology drug development Gursel Aktan and Merck women’s cancer team on just released positive OS data on KN 522. Outstanding news for high risk TNBC patients with this OS benefit confirmation. Amazing team dedication to breast cancer patients and hard efforts to meet challenges over many years during development to bring immunotherapy option to the beadside is simply inspirational.”
Read further.
Source: Tanja Obradovic/LinkedIn
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023